The representativeness of eligible patients in type 2 diabetes trials: A case study using GIST 2.0

Journal of the American Medical Informatics Association

Volumn 25, Issue 3, 2018, Pages 239-247

  Sen, Anando ^a   Goldstein, Andrew ^a   Chakrabarti, Shreya ^a   Shang, Ning ^a   Kang, Tian ^a   Yaman, Anil ^b   Ryan, Patrick B ^a,c   Weng, Chunhua ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical trials; Eligibility criteria; Metadata analysis; Population representativeness

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; DIABETIC PATIENT; DIET RESTRICTION; ELECTRONIC HEALTH RECORD; GLUCOSE BLOOD LEVEL; HISTOGRAM; HUMAN; ICD-9; KERNEL METHOD; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; QUANTITATIVE TRAIT; SENSITIVITY AND SPECIFICITY;

EID: 85043305792     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocx091     Document Type: Article

References (43)

1. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:1-14.
2. He Z, Ryan P, Hoxha J, Wang S, Carini S, Sim I, Weng C. Multivariate analysis of the population representativeness of related clinical studies. J Biomed Inform. 2016;60:66-76.
3. Wang TS, Hellkamp AS, Patel CB, Ezekowitz JA, Fonarow GC, Hernandez AF. Representativeness of RELAX-AHF clinical trial population in acute heart failure. Circ Cardiovasc Qual Outcomes. 2014;7:259-68.
4. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146:250-57.
5. Sen A, Ryan PB, Goldstein A, Chakrabarti S, Wang S, Koski E, Weng C. Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials. Ann NYAcad Sci. 2017;1387:34-43.
6. Weng C, Li Y, Ryan P, et al. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Appl Clin Inform. 2014;5:463-79.
7. Musen MA, Rohn JA, Fagan LM, Shortliffe EH. Knowledge engineering for a clinical trial advice system: Uncovering errors in protocol specification. Bull Cancer. 1987;74:291-96.
8. Ross J, Tu S, Carini S, Sim I. Analysis of eligibility criteria complexity in clinical trials. AMIA Summits Transl Sci Proc 2010;46-50.
9. Hao T, Rusanov A, Boland MR, Weng C. Clustering clinical trials with similar eligibility criteria features. J Biomed Inform. 2014;52:112-20.
10. Rubin DL, Gennari J, Musen MA. Knowledge representation and tool support for critiquing clinical trial protocols. Proc AMIA Annu Symp. 2000;724-28.
11. Weng, C. Optimizing clinical research participant selection with informatics. Trends Pharmacol Sci. 2015;36:706-09.
12. He Z, Ryan P, Hoxha J, Wang S, Carini S, Sim I, Weng C. Multivariate analysis of the population representativeness of related clinical studies. 2016;60:67-76.
13. Somerson JS, Bhandari M, Vaughan CT, Smith CS, Zelle BA. Lack of diversity in orthopaedic trials conducted in the United States. J Bone Joint Surg Am. 2014;96:e56.
14. Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol. 2004;3:627-30.
15. Hoertel N, Strat Y Le, Lavaud P, Dubertret C, Limosin F. Generalizability of clinical trial results for bipolar disorder to community samples. J Clin Psychiatry. 2013;74:265-70.
16. Sen A, Chakrabarti S, Goldstein A, Wang S, Ryan PB, Weng C. GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies. J Biomed Inform. 2016;63:325-36.
17. Pressler TR, Kaizar EE. The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias. Stat Med. 2013;32:3552-68.
18. Greenhouse JB, Kaizar EE, Kelleher K, Seltman H, Gardner W. Generalizing from clinical trial data: A case study. The risk of suicidality among pediatric antidepressant users. Stat Med. 2008;27:1801-13.
19. Weng C, Wu X, Luo Z, Boland MR, Theodoratos D, Johnson SB. EliXR: an approach to eligibility criteria extraction and representation. J Am Med Inform Assoc. 2011;18(Suppl 1):i116-24.
20. Hao T, Liu H, Weng C. Valx: a system for extracting and structuring numeric lab test comparison statements from text. Methods Inf Med. 2016;55:266-75.
21. Vijan S. Type 2 diabetes. Ann Intern Med. 2010;152:ITC315.
22. Richesson RL, Hammond WE, Nahm M, et al. Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. J Am Med Inform Assoc. 2013;20:e226-31.
23. Spratt SE, Pereira K, Granger BB, et al. Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus. J Am Med Inform Assoc. 2016;42:e121-28.
24. Anderson AE, Kerr WT, Thames A, Li T, Xiao J, Cohen MS. Electronic health record phenotyping improves detection and screening of type 2 diabetes in the general United States population: a cross-sectional, unselected, retrospective study. J Biomed Inform. 2016;60:162-68.
25. Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med Res Methodol. 2014;14:75.
26. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons; 1987.
27. Yao B, Zhu L, Jiang Q, Xia HA. Safety monitoring in clinical trials. Pharmaceutics. 2013;5:94-106.
28. International Council for Harmonisation. Safety Guidlines. 2016. http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.
29. Cancer.Net Editorial Board. Phases of Clinical Trials. 2015.
30. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996;14:1364-70.
31. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of results from the Systolic Blood Pressure Intervention Trial (SPRINT) to the US adult population. J Am Coll Cardiol. 2016;67:463-72.
32. Kadam RA, Borde SU, Madas SA, Salvi SS, Limaye SS. Challenges in recruitment and retention of clinical trial subjects. Perspect Clin Res. 2016;7:137-43.
33. Gelling L. Facing the Challenges of Recruitment to Clinical Trials - Clinfield. 2016. http://clinfield.com/2016/06/recruitment/.
34. Statler A, Radivoyevitch T, Siebenaller C, et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia. 2016;31(8):1808-15.
35. Galsky MD, Stensland KD, McBride RB, et al. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015;175:293.
36. Zaman MJ, Patel A, Chalmers J, et al. The effects of patient characteristics and geographical region on hospitalization in patients with Type 2 diabetes. Diabet Med. 2013;30:918-25.
37. Lopienski, K. Why do recruitment efforts fail to enroll enough patients? Nimblify, Inc. 2014. https://forteresearch.com/news/recruitment-efforts-fail-enroll-enough-patients/. Accessed June 20, 2017.
38. Bianchi A. Patient recruitment driving length and cost of oncology clinical trials. Int Pharm Ind. 2013;5:58-61.
39. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454-63.
40. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13:217.
41. Ruilope L, Hanefeld M, Lincoff AM, et al. Effects of the dual peroxisome proliferator-activated receptor-a/c agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014;15:180.
42. Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness of electronic health records. AMIA Annu Symp Proc. 2013;1472-77.
43. O'Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40:1620-39.